NCT02191397 - Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder | Biotech Hunter

Enrollment

534

Participants

Timeline

Start Date

February 10, 2015

Primary Completion Date

October 10, 2016

Study Completion Date

October 25, 2016

Conditions

Depressive Disorder, Major

Interventions

DRUG

Bupropion

Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.

DRUG

Bupropion Matching Placebo

Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding

DRUG

Escitalopram

Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.

DRUG

Escitalopram Matching Placebo

Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding

Trial Locations (20)

100083

GSK Investigational Site, Beijing

100088

GSK Investigational Site, Beijing

100096

GSK Investigational Site, Beijing

150070

GSK Investigational Site, Harbin

200030

GSK Investigational Site, Shanghai

200065

GSK Investigational Site, Shanghai

210029

GSK Investigational Site, Nanjing

310003

GSK Investigational Site, Hangzhou

410011

GSK Investigational Site, Changshacun

510180

GSK Investigational Site, Guangzhou

510370

GSK Investigational Site, Guangzhou

530021

GSK Investigational Site, Nanning

550004

GSK Investigational Site, Guiyang

650032

GSK Investigational Site, Kunming

710032

GSK Investigational Site, Xi'an

071000

GSK Investigational Site, Baoding

Unknown

GSK Investigational Site, Changsha

GSK Investigational Site, Taiyuan

GSK Investigational Site, Xi’an

GSK Investigational Site, Wuhan